The Searle Company Limited (SEARL): Corporate Analyst Briefing takeaways – By JS Research
Nov 27 2024
JS Global Capital
- The Searle Company Limited (SEARL) conducted its corporate briefing yesterday to discuss the company’s FY24 earnings and outlook. We present key highlights from the session.
- The company reported a consolidated topline of Rs29bn, up 14%YoY during FY24. Gross margin improved ~3ppts YoY to 46.6%. However, SEARL reported a loss of Rs2.4bn, owing to a loss from discontinued operations of subsidiary to the tune of Rs3.8bn.
- The leading brands under therapeutic category of SEARL include Hydrllin, Nuberol, Peditral, Extor, Rotec, Gravinate, and Venofer.
Current:
Open:
Volume:
Change: ()
High:
Low:
52 Week High:
Vol Avg(12 m):
Free Float:
52 Week Low:
Market Cap:
Total Share:
Relative Strength Index (RSI)
RSI:
MACD Signals
MACD DAILY:
MACD WEEKLY:
Simple Moving Avg (SMA)
SMA(10):
SMA(30):
SMA(60):
SMA(200):
Performance
One Month:
Three Months:
Six Months:
Twelve Months:
Support & Resistance
Support 1:
Resistance 1:
Support 2:
Resistance 2:
High & Lows
Period
High
Low